Cryoport Misses On EPS But Beats On Revenue And Raises Guidance Again, While Its Regulatory Catalyst Calendar Keeps Shrinking

Cryoport (NASDAQ: CYRX) reported a third-quarter loss of $0.25 per share, missing the -$0.19 consensus and the -$0.21 Earnings Whisper number by 19.0%. The loss widened from $0.18 a year ago, a 38.9% year-over-year earnings decline. The top line told a different story. Revenue of $50.22 million beat the $48.68 million consensus by 3.2% and grew 13.5% year over year. Management also raised full-year 2026 revenue guidance for the second time this year, to $197 million to $199 million. The EPS miss is real on a GAAP basis, but it says little about how the core business performed. The more important tension is between improving operations and a regulatory catalyst calendar that keeps slipping.

The quality of the miss deserves scrutiny because most of the damage came below the operating line. Loss from operations actually narrowed to $8.8 million from $9.9 million a year earlier. Other expense, however, swung to a $4.4 million charge from $0.5 million of income, driven largely by a $4.2 million unrealized loss on investments. Investment income also slipped to $3.0 million from $3.4 million. Results to common holders also carry a recurring $2.0 million paid-in-kind preferred dividend. Adjusted EBITDA from continuing operations improved to a positive $1.1 million, compared with -$0.6 million a year ago, $0.4 million in Q2, and -$0.6 million in Q1. This is the second straight positive quarter. Gross margin is the one operating blemish. Consolidated gross margin slipped to 47.5% from 48.2% as Life Sciences Products margin fell to 43.6% from 46.4%. Services margin, by contrast, improved to 50.4%.

Beneath the headline, the services engine is accelerating:

• Life Sciences Services grew 18%, up from 15% in Q2.
• Commercial cell and gene therapy revenue grew 20%, compared with 9% commercial growth in the second quarter.
• BioStorage/BioServices rose 25% and has now grown more than 20% for seven consecutive quarters.
• Products returned to 8% growth after a flat Q2. Management called it MVE's best quarter in roughly three years, with growth in every region.

Sequentially, revenue climbed from $47.8 million in Q1 to $49.0 million in Q2 and $50.2 million in Q3. Pipeline breadth also improved. Supported clinical trials reached a record 788, including 99 in Phase 3, and Phase 3 additions totaled 13 year-to-date versus five in all of last year. Management attributed this to a rebound in funding. Its tone shifted from Q2's cautious reaffirmation to explicitly bullish language. Management also reiterated long-term targets of 55% gross margin and 30% adjusted EBITDA margin.

Bears still have legitimate ammunition, and most of it sits in the regulatory calendar:

• **Filings:** Coming into 2026, management expected 13 customer BLA/MAA filings. After Q3, the year has produced two filings, with roughly five more possible, and four have slipped into 2027.
• **Approvals:** Expectations have fallen from nine at the start of the year to one achieved (Replimune's TUDRIQEV) plus two possible. Both pending approvals carry Q4 PDUFA dates, and management also flagged a potential first autoimmune cell therapy approval in early 2027.
• **Fourth-quarter outlook:** Raised guidance implies Q4 revenue of about $50 million to $52 million, essentially flat to modestly higher sequentially. That outlook excludes new approvals, and management cited government and external uncertainty.
• **Products durability:** Part of MVE's strength leans on animal health, which management described as cyclical.
• **Near-term margins:** New bioservices sites in Paris and Santa Ana will initially weigh on margins as the network build-out runs toward substantial completion in 2027.

The balance sheet gives Cryoport ample room to absorb these delays. It holds $393.1 million in cash and short-term investments against $186 million of convertible notes now classified as current.

The market had already moved toward the bullish view before the report. Earnings Whispers investor sentiment rose sharply, from 0.36 at the prior report to 0.73. Shares entered the release at $16.70, up 9.7% from the opening price after the August report. That left the stock about 25% above its 200-day moving average and 17% above its inter-earnings low of $14.32. However, the stock was also 11.5% below the 52-week high of $18.88 set on October 28, so it had already given back part of its pre-earnings run. Momentum and AVWAP trend readings remain positive, while price trend is neutral. Expectations were elevated, which makes a GAAP miss and a soft implied fourth quarter harder to dismiss than they would be in a washed-out setup.

The bottom line is that Cryoport's operating story improved more than its EPS line suggests. Services growth is accelerating, adjusted EBITDA is now consistently positive, and the revenue outlook has been raised twice. The headline loss was inflated by investment marks rather than operating deterioration. The offsetting problem is that the customer approval cycle keeps slipping into 2027, and Q4 guidance implies a pause in sequential growth. With sentiment already running hot and shares well above long-term trend, the stock is now more dependent on Q4 PDUFA outcomes and on proof that margins can expand as new sites mature.

Read our earnings preview for Cryoport, Inc.: https://www.earningswhispers.com/article/CYRX/22271

This earnings review was originally published on Earnings Whispers.

This article is for informational purposes only and is not investment advice. Earnings Whispers and its staff may hold positions in the securities mentioned. It is AI-assisted, based on proprietary Earnings Whispers data and company reports, and edited by Earnings Whispers staff.